본문 바로가기 주메뉴 바로가기 하단영역 바로가기

현재 브라우저는 iframe을 지원하지 않습니다.

Home > About Us

We are dedicated to increase treatment effects through new pharmaceutical formulations that are most patient-friendly.

With the growing elderly population, there is the need for more patient-friendly dosage forms, and OD!FS® will meet this need.

As our platform technologies have already been applied to various indications, we have seen commercial achievements with renowned domestic and international partners. We also own OD!FS® pipeline products that are currently in the clinical trial or research stages. Beyond these, we are planning to expand our business areas to new formulations that offer increased convenience of administration, such as pro-drugs and microbiome-based products.

History

2019

  • Site for GMP factory contracted (Osong)

2018

  • R&D center relocated

2017

  • ISO 9001 certified
  • Certified as a venture corporation
  • Patent of OD!FS® technology registered in the US

2016

  • Patent of OES technology registered in Korea

2015

  • Renamed CI as Corepharm Bio Co., Ltd.
  • Tadalafil OD!FS® launched

2014

  • Desmopressin OD!FS® launched
  • Formulation R&D center founded

2013

  • Won the Gyeonggi Entrepreneur Export Award
  • Won the Trade, Industry and Energy Ministerial Award
  • Patent of OD!FS® technology registered in Korea

2009

  • Relocated to Seongnam-si

2003

  • Medinex Pharm Co., Ltd. incorporated